Rock Springs Capital XLO Position
ExitedRock Springs Capital exited their position in Xilio Therapeutics, Inc. (XLO) in Q1 2025, after holding the stock for 9 quarters.
The position was first reported in Q1 2023 and has been tracked across 9 quarterly 13F filings.
1 insider purchase totaling $44K has been filed in the last 90 days, providing an additional conviction signal.
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Full company profile →Short Interest
3.9%
5.2 days to cover
Insider Buys (90d)
1
$44K total
Rock Springs Capital XLO Position History
Frequently Asked Questions
Does Rock Springs Capital own XLO?
No. Rock Springs Capital exited their position in Xilio Therapeutics, Inc. (XLO) in Q1 2025. They previously held the stock for 9 quarters.
How many hedge funds own XLO?
Based on the 20 specialist biotech hedge funds tracked by BiotechEdge, no tracked fund currently holds an active position in XLO.
When did Rock Springs Capital first buy XLO?
Rock Springs Capital's position in XLO was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's XLO position increasing or decreasing?
Rock Springs Capital completely exited their XLO position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
XLOCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →